Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
暂无分享,去创建一个
Depei Wu | F. Xia | N. Ping | L. Kang | Lei Yu | Zhengming Jin | D. Kong | Changju Qu | Hai Liu | Peng Wang | Qian Zhu | R. Zou | Z. Jin | Q. Zhu | Liqing Kang
[1] Jianfeng Zhou,et al. CD19/CD22 CAR T cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas: Combined CAR T Cell Therapy and Transplantation. , 2021, Transplantation and cellular therapy.
[2] K. Davis,et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.
[3] A. Nagler,et al. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study , 2021, Cancer Immunology Research.
[4] J. Mu,et al. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy , 2021, OncoTargets and therapy.
[5] Depei Wu,et al. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma , 2021, Frontiers in Oncology.
[6] Depei Wu,et al. Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations , 2021, Bone Marrow Transplantation.
[7] K. Davis,et al. CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. , 2020, Blood.
[8] D. Maloney,et al. Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure. , 2020, Blood.
[9] C. Clouser,et al. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib , 2020, Journal of immunotherapy.
[10] Depei Wu,et al. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden , 2020, Journal of immunotherapy.
[11] Xiaoyuan He,et al. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma , 2019, Front. Oncol..
[12] C. Clouser,et al. Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide , 2019, Molecular Cancer Therapeutics.
[13] Hui Xu,et al. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma , 2019, OncoTargets and therapy.
[14] D. Jäger,et al. Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients , 2019, International journal of cancer.
[15] Depei Wu,et al. Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells , 2019, Bone Marrow Transplantation.
[16] I. Flinn,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.
[17] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.
[18] Y. Li,et al. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. , 2018, Experimental hematology.
[19] A. Annoni,et al. Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens , 2018, Nature Communications.
[20] A. Krishnan,et al. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma , 2017, Clinical Cancer Research.
[21] C. Hourigan,et al. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome , 2017, Clinical Cancer Research.
[22] Paul G. Thomas,et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation , 2017, Cell.
[23] F. Gao,et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] J. Lang,et al. Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents , 2015, Front. Immunol..
[25] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[26] S. Karlsson,et al. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy , 2013, Cancer Gene Therapy.
[27] S. Karlsson,et al. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy , 2013, Cancer Gene Therapy.
[28] Li-li Wang,et al. Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses , 2013, PloS one.
[29] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.